<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The first publications regarding clinical use of <z:chebi fb="5" ids="15891">taurine</z:chebi> were Italian reports claiming therapeutic efficacy in <z:mp ids='MP_0006112'>angina</z:mp>, <z:hpo ids='HP_0004417'>intermittent claudication</z:hpo> and symptomatic cerebral <z:hpo ids='HP_0002634'>arteriosclerosis</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>A down-regulation of neutrophil activation and endothelial <z:e sem="disease" ids="C0001511" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">adhesion</z:e> might plausibly account for these observations </plain></SENT>
<SENT sid="2" pm="."><plain>Endothelial platelet-activating factor (PAF) is a crucial stimulus to neutrophil <z:e sem="disease" ids="C0001511" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">adhesion</z:e> and activation, whereas endothelial nitric <z:chebi fb="177" ids="25741,29356">oxide</z:chebi> (NO) suppresses PAF production and acts in various other ways to antagonize binding and activation of neutrophils </plain></SENT>
<SENT sid="3" pm="."><plain><z:chebi fb="0" ids="24757">Hypochlorous acid</z:chebi> (<z:chebi fb="0" ids="24757">HOCl</z:chebi>), a neutrophil product which avidly oxidizes many sulfhydryl-dependent proteins, can be expected to inhibit NO synthase while up-regulating PAF generation; thus, a vicious circle can be postulated whereby <z:chebi fb="0" ids="24757">HOCl</z:chebi> released by marginating neutrophils acts on capillary or venular endothelium to promote further neutrophil <z:e sem="disease" ids="C0001511" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">adhesion</z:e> and activation </plain></SENT>
<SENT sid="4" pm="."><plain><z:chebi fb="5" ids="15891">Taurine</z:chebi> is the natural detoxicant of <z:chebi fb="0" ids="24757">HOCl</z:chebi>, and thus has the potential to intervene in this vicious circle, promoting a less adhesive endothelium and restraining excessive neutrophil activation </plain></SENT>
<SENT sid="5" pm="."><plain>Agents which inhibit the action of PAF on neutrophils, such as ginkgolides and pentoxifylline, have documented utility in ischemic disorders and presumably would complement the efficacy of <z:chebi fb="5" ids="15891">taurine</z:chebi> in this regard </plain></SENT>
<SENT sid="6" pm="."><plain>Fish oil, which inhibits endothelial expression of various <z:e sem="disease" ids="C0001511" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">adhesion</z:e> factors and probably PAF as well, and which suppresses neutrophil <z:chebi fb="0" ids="25029">leukotriene</z:chebi> production, may likewise be useful in <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> </plain></SENT>
<SENT sid="7" pm="."><plain>These agents may additionally constitute a non-toxic strategy for treating <z:e sem="disease" ids="C1290884" disease_type="Disease or Syndrome" abbrv="">inflammatory disorders</z:e> in which activated neutrophils play a prominent pathogenic role </plain></SENT>
<SENT sid="8" pm="."><plain>Double-blind studies to confirm the efficacy of <z:chebi fb="5" ids="15891">taurine</z:chebi> in symptomatic <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> are needed </plain></SENT>
</text></document>